secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001828185-24-000083
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026
--------------------------------------------------------------------------------

- Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.
- Cash and equivalents $106.1M at Sep 30, 2024, down from $117.8M at Jun 30; cash runway now into Q2 2026.
- HBV003 trial of VTP-300 in chronic hepatitis B fully enrolled (121 participants); updated data at AASLD Nov 2024 as late-breaking abstracts.
- VTP-1000 Phase 1 AVALON trial in celiac disease initiated; VTP-850 Phase 1 PCA001 trial completed enrollment (22 participants).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000083/0001828185-24-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000083/brns-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer